Installation of the latest Shimadzu LC-MS/MS 8060 system increases our analytical capacity and sensitivity, enabling faster turnaround times for bioequivalence studies.
The new system joins our existing fleet of LC-MS/MS instruments, bringing our total platform count to six. This expansion was driven by growing demand from international pharmaceutical clients and our commitment to maintaining state-of-the-art infrastructure.
Technical capabilities
The Shimadzu 8060 offers sub-picogram detection limits and significantly reduced cycle times, allowing our bioanalytical team to process a higher volume of samples without compromising data quality or regulatory compliance.
Impact on study timelines
With the additional instrument capacity, PRU can now accommodate larger study cohorts and parallel studies simultaneously — reducing overall study timelines by up to 30% for clients with time-sensitive regulatory submissions.
